Monoclonal antibodies in frontline acute lymphoblastic leukemia

被引：5

作者：

Chew, Serena ^{[1
]}

Jammal, Nadya ^{[1
]}

Kantarjian, Hagop ^{[1
]}

Jabbour, Elias ^{[1
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, 1515 Holcombe Blvd,Box 428, Houston, TX 77030 USA

来源：

BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2020年 / 33卷 / 04期

关键词：

Acute lymphoblastic leukemia; ALL; Monoclonal antibodies; Adult; Frontline; ACUTE LYMPHOCYTIC-LEUKEMIA; MINIMAL RESIDUAL DISEASE; INOTUZUMAB OZOGAMICIN; ADULT BURKITT; HYPER-CVAD; SINGLE-ARM; PHASE-II; BLINATUMOMAB; RITUXIMAB; THERAPY;

D O I：

10.1016/j.beha.2020.101226

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The recent development of monoclonal antibodies targeting CD19, CD20, and CD22 has significantly improved long-term survival in patients with acute lymphoblastic leukemia (ALL), both in the frontline and relapsed and refractory setting. The incorporation of CD20 monoclonal antibodies (e.g. rituximab) has improved cure rates from 35% to 50% in those with precursor B-cell ALL and from 40 to 80% in those with Burkitt leukemia. More novel antibodies, such as drug conjugates antibodies (e.g. inotuzumab ozogamicin) and bispecific T-cell engagers (e.g. blinatumomab), have shown significant promise in improving outcomes in the relapsed and refractory setting and are currently being studied in the frontline setting, with hopes to further improve long-term outcomes. In this chapter, we will review the role of monoclonal antibodies and how the incorporation of these agents has revolutionized and changed the treatment management of ALL in the frontline setting.

引用

页数：8

共 49 条

[1] Results of SWOG 1318: A Phase 2 Trial of Blinatumomab Followed By Pomp (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) Maintenance in Elderly Patients with Newly Diagnosed Philadelphia Chromosome Negative B-Cell Acute Lymphoblastic Leukemia [J].

Advani, Anjali S. ;

Moseley, Anna ;

O'Dwyer, Kristen Marie ;

Wood, Brent ;

Fang, Min ;

Wieduwilt, Matthew J. ;

Aldoss, Ibrahim ;

Park, Jae H. ;

Klisovic, Rebecca ;

Baer, Maria R. ;

Stock, Wendy ;

Bhave, Rupali ;

Othus, Megan ;

Litzow, Mark R. ;

Stone, Richard M. ;

Erba, Harry P. .

BLOOD, 2018, 132

[2] A phase 2 study of hyper-CVAD plus ofatumumab as frontline therapy in CD20+acute lymphoblastic leukemia (ALL): Updated results. [J].

Bazarbachi, Abdul Hamid ;

Yilmaz, Musa ;

Ravandi, Farhad ;

Thomas, Deborah A. ;

Khouri, Maria ;

Garcia-Manero, Guillermo ;

Garris, Rebecca S. ;

Cortes, Jorge E. ;

Short, Nicholas James ;

Sasaki, Koji ;

Issa, Ghayas C. ;

Koller, Paul B. ;

Kadia, Tapan M. ;

Verstovsek, Srdan ;

Daver, Naval Guastad ;

Jain, Nitin ;

Konopleva, Marina ;

O'Brien, Susan Mary ;

Jabbour, Elias ;

Kantarjian, Hagop M. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)

[3]

Brown PA, 2019, BLOOD, P134, DOI DOI 10.1182/BLOOD-2019-132435.LBA-1-LBA-1

[4] Dasatinib-Blinatumomab Combination for the Front-Line Treatment of Adult Ph plus ALL Patients. Updated Results of the Gimema LAL2116 D-Alba Trial [J].

Chiaretti, Sabina ;

Bassan, Renato ;

Vitale, Antonella ;

Elia, Loredana ;

Piciocchi, Alfonso ;

Puzzolo, Cristina ;

Canichella, Martina ;

Ferrara, Felicetto ;

Lunghi, Monia ;

Fabbiano, Francesco ;

Bonifacio, Massimiliano ;

Fracchiolla, Nicola ;

Salutari, Prassede ;

Mancino, Alessandra ;

Vignetti, Marco ;

Guarini, Anna ;

Rambaldi, Alessandro ;

Foa, Robin .

BLOOD, 2019, 134

[5] RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma [J].

Corazzelli, Gaetano ;

Frigeri, Ferdinando ;

Russo, Filippo ;

Frairia, Chiara ;

Arcamone, Manuela ;

Esposito, Gennaro ;

De Chiara, Annarosaria ;

Morelli, Emanuela ;

Capobianco, Gaetana ;

Becchimanzi, Cristina ;

Volzone, Francesco ;

Saggese, Mariangela ;

Marcacci, Giampaolo ;

De Filippi, Rosaria ;

Vitolo, Umberto ;

Pinto, Antonio .

BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (02) :234-244

[6] Blinatumomab plus Ponatinib for Relapsed Ph1-Positive Acute Lymphoblastic Leukemia: The French Experience [J].

Couturier, Marie-Anne ;

Thomas, Xavier ;

Huguet, Francoise ;

Berthon, Celine ;

Simand, Celestine ;

Hicheri, Yosr ;

Hunault, Mathilde ;

Chevallier, Patrice .

BLOOD, 2018, 132

[7] Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study [J].

DeAngelo, Daniel J. ;

Stock, Wendy ;

Stein, Anthony S. ;

Shustov, Andrei ;

Liedtke, Michaela ;

Schiffer, Charles A. ;

Vandendries, Erik ;

Liau, Katherine ;

Ananthakrishnan, Revathi ;

Boni, Joseph ;

Laird, A. Douglas ;

Fostvedt, Luke ;

Kantarjian, Hagop M. ;

Advani, Anjali S. .

BLOOD ADVANCES, 2017, 1 (15) :1167-1180

[8] UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia [J].

Fielding, Adele K. ;

Rowe, Jacob M. ;

Buck, Georgina ;

Foroni, Letizia ;

Gerrard, Gareth ;

Litzow, Mark R. ;

Lazarus, Hillard ;

Luger, Selina M. ;

Marks, David I. ;

McMillan, Andrew K. ;

Moorman, Anthony V. ;

Patel, Bella ;

Paietta, Elisabeth ;

Tallman, Martin S. ;

Goldstone, Anthony H. .

BLOOD, 2014, 123 (06) :843-850

[9] The History of Leukemia Therapy-A Personal Journey [J].

Freireich, Emil J. .

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2012, 12 (06) :386-392

[10] Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia [J].

Goekbuget, Nicola ;

Dombret, Herve ;

Bonifacio, Massimiliano ;

Reichle, Albrecht ;

Graux, Carlos ;

Faul, Christoph ;

Diedrich, Helmut ;

Topp, Max S. ;

Brueggemann, Monika ;

Horst, Heinz-August ;

Havelange, Violaine ;

Stieglmaier, Julia ;

Wessels, Hendrik ;

Haddad, Vincent ;

Benjamin, Jonathan E. ;

Zugmaier, Gerhard ;

Nagorsen, Dirk ;

Bargou, Ralf C. .

BLOOD, 2018, 131 (14) :1522-1531

← 1 2 3 4 5 →